Objective: This Phase II study was carried out to investigate the efficacy, safety and pharmacokinetics of topotecan in Japanese patients with relapsed ovarian carcinoma. Methods: Patients with relapsed ovarian carcinoma after having received one regimen containing platinum-based chemotherapy were eligible for this study. Topotecan was administered at 1.2 mg/m 2 /day for five consecutive days, repeated every 3 weeks. Results: Seventy-two patients were enrolled in the study. The response rate was 28.2% (95% confidence interval, 18.1 -40.1%). Signs of myelosuppression, such as neutropenia (Grade 3, 12.5%; Grade 4, 83.3%), thrombocytopenia (Grade 3, 36.2%; Grade 4, 4.2%) and decreased hemoglobin (Grade 3, 36.1%; Grade 4, 11.1%), were the most common hematological toxicities. Grade 3 febrile neutropenia occurred in 5 (6.9%) patients. There was little intraindividual or interindividual variability in the pharmacokinetics of topotecan. Conclusions: Topotecan at 1.2 mg/m 2 /day is an effective and tolerable therapeutic option for Japanese patients with relapsed ovarian carcinoma.
INTRODUCTION
Topotecan is a water-soluble, semisynthetic analogue of camptothecin, which is a plant alkaloid first isolated from Camptotheca acuminata, a tree native to China. Topotecan acts by binding to the topoisomerase I (Topo-I) complex, thereby preventing the DNA relegation step during replication and leading to cell death (1) . Topotecan has a lactone moiety and is reversibly hydrolyzed from the active, lactone form to a less potent, hydroxyl acid form in a pH-dependent reaction; at physiologic pH, the equilibrium favors the hydroxyl acid form (2) . Although topotecan and irinotecan are both novel camptothecin derivatives and show similar cytotoxic activity through inhibition of Topo-I, their spectra of antitumor activity for human carcinomas and their toxicity profiles are very different. The critical toxicity for topotecan is myelosuppression, whereas for irinotecan it is gastrointestinal toxicity (1) .
As a single agent, topotecan has been demonstrated to show antitumor activity against relapsed ovarian carcinoma in non-Japanese patients. In Phase II studies, topotecan achieved a response rate (RR; defined as the ratio between the number of patients with a complete response or partial response and the total number of patients) and a disease # The Author (2010). Published by Oxford University Press. All rights reserved.
Jpn J Clin Oncol 2011;41(3)320 -327 doi:10.1093/jjco/hyq192 Advance Access Publication 25 October 2010 control rate (defined as the ratio between the number of patients with a complete response, partial response or stable disease and the total number of patients) of 14 -16% and 37 -74%, respectively (3 -5) . Subsequently, a large Phase III comparative trial of topotecan versus paclitaxel showed a similar RR and survival (6) . On the basis of those results, topotecan has been approved as a treatment for relapsed ovarian carcinoma in more than 80 countries, including North and South American, European and Asian countries, and is widely used today.
In Japan, an early Phase II study found that topotecan, at a dose of 1.2 mg/m 2 /day, may be effective and safe in the treatment of ovarian carcinoma. Accordingly, we conducted a Phase II study to investigate the efficacy, safety and pharmacokinetics of topotecan (1.2 mg/m 2 /day once daily for five consecutive days, every 3 weeks) in Japanese patients with relapsed ovarian carcinoma.
PATIENTS AND METHODS

STUDY DESIGN
This study was a multicenter, non-randomized, open-label trial conducted to evaluate the efficacy, safety and pharmacokinetics of topotecan in Japanese patients with relapsed ovarian carcinoma previously treated with platinum-based chemotherapy.
The primary endpoint was the RR, defined as the percentage of patients achieving a complete or partial response. The secondary endpoints were the incidence, severity, seriousness and causality of adverse drug reactions. Computed tomography (CT) or magnetic resonance imaging (MRI) examination was performed during each chemotherapy cycle. Final evaluation of the antitumor effect by imaging modalities, including either CT or MRI, was performed by an independent radiological review committee.
Written informed consent was obtained from all patients enrolled in the study. The study was conducted in compliance with the good clinical practice guidelines and the Declaration of Helsinki, and the study protocol was approved by the local institutional review boards.
PATIENTS
A total of 72 patients from 33 institutions throughout Japan were enrolled in the study. Patients with relapsed ovarian carcinoma previously treated with platinum-based chemotherapy were eligible for this study. Only patients who had undergone one previous chemotherapy regimen were enrolled.
For enrollment, patients had to be between 20 and 75 years of age, with histologically confirmed ovarian surface epithelial-stromal tumors and measurable disease. Other enrollment criteria were as follows: an Eastern Cooperative Oncology Group (ECOG) performance status (P.S.) of 0 to 2; an expected survival of 3 months or longer; laboratory criteria (hemoglobin [Hb], 9.0 g/dl; white blood cell count [WBC], 4000 -10 000/mm 3 ; neutrophil count, 2000/mm 3 ; platelet count, 100 000/mm 3 ; total bilirubin, 1.5 mg/dl; alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase, 2.5 times the institutional upper limit of normal [ULN] ; serum creatinine, the institutional ULN; and 24 h creatinine clearance 60 ml/min); and the ability to be hospitalized during the first treatment cycle.
The exclusion criteria were as follows: the presence of a serious infection or complication; any serious gastrointestinal disorder or hemorrhage; pleural effusion or ascites requiring therapeutic intervention such as puncture and drainage or drug administration; a history or complication of interstitial pneumonia, radiation pneumonia or pulmonary fibrosis; ileus; active symptomatic central nervous system metastasis; active double-carcinoma; having undergone bone marrow transplantation; a history of serious hypersensitivity; pregnant or breast-feeding, the possibility of pregnancy or an intention to become pregnant; poorly controlled diabetes; and prior administration of a Topo-I inhibitor.
MEDICATION
Eligible patients were intravenously administered topotecan at a dose of 1.2 mg/m 2 /day as a 30 min infusion for five consecutive days, every 3 weeks. This treatment was repeated for at least four cycles unless there was no progressive disease (PD).
Prior to proceeding to the next cycle, all patients were confirmed to meet each of the following criteria: neutrophil count 1500/mm 3 ; platelet count 100 000/mm 3 ; creatinine ULN at each participating medical institution; non-hematological toxicity Grade 2 (except for nausea, vomiting, anorexia, fatigue and alopecia); and the absence of PD according to the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.0) (7) .
The dose of the next cycle was reduced by 0.2 mg/m 2 /day if any of the following criteria were met: Grade 3 neutropenia (neutrophil count ,1000/mm 3 ) with a fever (38.58C); Grade 4 neutropenia (neutrophil count ,500/mm 3 ) lasting 7 days in spite of administration of granulocyte colony-stimulating factor (G-CSF); thrombocytopenia (platelet count ,25 000/mm 3 ); or the investigator considered it appropriate. The minimal treatment dose was set at 1.0 mg/m 2 /day. G-CSF was administered if a patient met any of the following criteria: (i) neutrophil count ,1000/mm 3 with a fever (38.58C); (ii) neutrophil count ,500/mm 3 ; or (iii) experience of either (i) or (ii) in the prior cycle and a neutrophil count ,1000/mm 3 in the following cycle.
EVALUATION OF RESPONSE AND SAFETY
The tumor response was classified into complete response (CR), partial response (PR), stable disease (SD), PD and not evaluated (NE) according to the RECIST guideline (version 1.0) (7). 'Confirmed duration' of SD was defined as a duration of six consecutive weeks or longer after the start of administration. The RR was calculated as the proportion of enrolled patients showing CR or PR. Adverse events were classified into Grades 1 through 5 according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0, Japanese Version JCOG/ JSCO.
PHARMACOKINETICS
Blood samples were collected pre-dosing and at 0.5, 1, 2, 4, 8, 12 and 24 h after the start of infusion on day 1 and day 5 of drug administration.
Plasma concentrations of the closed-ring form of topotecan and total topotecan, defined as the sum of the closedand open-ring forms, were able to be determined for seven patients who provided consent for investigation of the pharmacokinetics. The closed-ring form of topotecan and total topotecan were measured by a modified high-performance liquid chromatography method using fluorescence detection (8) . For both analyses, the lower limit of quantification was 0.05 ng/ml.
The pharmacokinetic parameters were calculated for each patient using the non-compartmental model of the software program, WinNonlin Professional (Pharsight Corporation, Mountain View, CA, USA). The following pharmacokinetic parameters were determined: peak concentration (C max ), terminal plasma half-life (T 1/2 ), concentration-time curve extrapolated from time 0 to infinity on day 1 (AUC inf ), area-under-concentration-time curve from time 0 to the end of dosing on day 5 (AUC 0-TAU ), plasma clearance on day 1 (CL p ), plasma clearance at steady state on day 5 (CL ss ), mean residence time extrapolated to infinity (MRT inf ), volume of distribution at steady state (V ss ) and accumulation ratio (R).
SAMPLE SIZE AND STATISTICAL ANALYSIS
Sample size calculations were based on the results of two early Phase II clinical trials in relapsed ovarian carcinoma patients in Japan. On the basis of the manufacturer's information (unpublished data), the RR in patients who had been administered one regimen of previous chemotherapy was 22.2% (2 of 9 patients) when using a topotecan starting dose of 1.2 mg/m 2 /day in those previous trials. Assuming that the expected RR would be 22% and the threshold RR 10%, we calculated the required sample size with an a of 0.05 (two-sided test) and a power of 80% (12b). We estimated that 71 evaluable patients would be required for this study. If 13 or more patients had responded by the end of the study, this regimen would be declared promising in this patient population. The corresponding 95% confidence interval (CI) of the RR was calculated on the basis of the binomial distribution.
The efficacy analysis was performed for the full analysis set (FAS), consisting of all patients who met the inclusion criteria but none of the exclusion criteria. The safety analysis included all patients who received at least one dose of topotecan. All analyses and tabulations were performed using SAS version 8.2 on a PC platform.
RESULTS
PATIENT CHARACTERISTICS
Seventy-two patients were enrolled in the study between July 2004 and February 2006. After the exclusion of one patient who had ascites that required puncture and drainage, 71 patients were defined as the FAS. Since all 72 patients received topotecan at least once, they were all included in the safety analysis set. For seven patients, drug concentrations in the plasma were measured to perform pharmacokinetic analysis.
The patient characteristics are shown in Table 1 . The median age was 60.0 years (range, 36 -74). Forty-eight patients had serous adenocarcinoma, 11 had endometrioid adenocarcinoma, 7 had clear cell adenocarcinoma, 3 had mucinous adenocarcinoma and 1 each had undifferentiated carcinoma, transitional cell carcinoma and another type of carcinoma. The ECOG P.S. was 0 in 58 patients, 1 in 13 and 2 in 1. The chemotherapy-free period after the previous chemotherapy was 4 weeks to 6 months in 37.5% (27 of 72) and more than 6 months in 62.5% (45 of 72). The previous chemotherapy regimen consisted of paclitaxel and carboplatin in 79.2% (57 of 72) of the patients, docetaxel and carboplatin in 9.7% (7 of 72), docetaxel and cisplatin in 2.8% (2 of 72), cisplatin and carboplatin in 2.8% (2 of 72) and four other chemotherapy regimens in 5.6% (4 of 72). Five patients had received radiotherapy and 71 had undergone surgery. Five patients had pleural effusion and 10 had ascites.
A total of 371 cycles of topotecan were administered to the 72 patients, and the median number of cycles administered was 4.0 (range, 1 -22 cycles). The dose of topotecan was reduced in nine patients (12.5%). Three of those reductions were for febrile neutropenia, three were because the investigator was concerned about myelosuppression, two were for Grade 4 thrombocytopenia and one was for Grade 4 thrombocytopenia and febrile neutropenia. The schedule of administration of topotecan was delayed in 213 of the 371 cycles (57.4%). Table 2 compiles the results for the tumor response by the histological type and the time interval following previous chemotherapy.
RESPONSE
For the total 71 patients in the FAS, the antitumor effect was CR in 2 patients, PR in 18, SD in 35, PD in 14 and NE in 2. The overall RR was calculated to be 28.2% (95% CI, 18.1 -40.1%). The two NE patients received only one treatment cycle due to toxicity.
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The RR results by histological subtype, including serous adenocarcinoma, endometrioid adenocarcinoma, clear cell adenocarcinoma and mucinous adenocarcinoma, were 31.9% (15 of 47 patients), 9.1% (1 of 11), 14.3% (1 of 7) and 33.3% (1 of 3) , respectively. Stratification of the patients based on the time interval following previous chemotherapy, i.e. 4 weeks to 6 months and more than 6 months, showed RR results of 11.5% (3 of 26) and 37.8% (17 of 45), respectively.
The RRs with each of the previous chemotherapy regimens, i.e. paclitaxel and carboplatin, docetaxel and carboplatin, docetaxel and cisplatin, cisplatin and carboplatin, and four other chemotherapy regimens were 26.8% (15 of 56 patients), 28.6% (2 of 7), 50.0% (1 of 2), 0% (0 of 2) and 50.0% (2 of 4), respectively.
The antitumor effects and RR, classified on the basis of whether or not dose reduction had been performed, are shown in Table 3 . Eight of the 71 patients in the FAS were treated at a reduced dose of 1.0 mg/m 2 /day. The RR with the dose reduction regimen, 25.0%, was not substantially below the 28.6% RR with the study regimen (Table 3) .
SAFETY
Adverse drug reactions due to topotecan were reported in all 72 patients. Table 4 shows the major adverse drug reactions The median time to nadir for WBCs, neutrophils, Hb and platelets from the start of administration was 9.0, 10.0, 11.0 and 14.0 days, respectively. The median times for recovery of neutrophils and platelets to a level permitting administration of topotecan in the next cycle were 7.0 and 11.0 days, respectively. Grade 3 or 4 non-hematological adverse drug reactions occurring at an incidence of 5% or greater were anorexia, 9.7% (7 of 72) and febrile neutropenia, 6.9% (5 of 72).
One patient died 22 days after two cycles of topotecan administration. The main cause of death was considered to be rapid progression of the primary disease.
PHARMACOKINETICS
The pharmacokinetics were evaluated for seven patients. Figure 1 depicts the average plasma concentration-time curves for the closed-ring form of topotecan and total topotecan (the sum of the closed-and open-ring forms) at a dose of 1.2 mg/m 2 on each of day 1 and day 5. The pharmacokinetic parameters are summarized in Table 5 .
The plasma concentrations of both the closed-ring form of topotecan and total topotecan peaked (i.e. C max ) upon completion of the infusion on both day 1 and day 5 and then decreased in a biphasic manner with a T 1/2 of about 5 h. No marked differences were observed in the pharmacokinetic parameters of either the closed-ring form of topotecan or total topotecan between day 1 and day 5, suggesting that there is little intraindividual variability in the pharmacokinetics. The interpatient variation was also small, being ,30% of the coefficient of variation. There was no accumulation in the plasma as a result of daily administration of topotecan for five consecutive days.
DISCUSSION
We evaluated the efficacy, safety and pharmacokinetics of topotecan in Japanese patients with relapsed ovarian carcinoma after one platinum-based regimen. Historically, improvement in the treatment outcomes for ovarian carcinoma was seen following the introduction of cisplatin therapy. However, the 5 year survival rate for advanced Stages III and IV remained at only 20%, making this the most lethal gynecological malignancy.
Subsequently, paclitaxel was introduced as a therapeutic drug, and the prognosis of patients with advanced ovarian carcinoma clearly improved, with a 5 year survival rate of 30%. However, the 10 year survival rate is 10%, which is still not satisfactory (9) . Moreover, 50 -75% of responders experience disease relapse within 18 months after completing the first-line therapy and then require further systemic therapy using multiple agents (10) . Therefore, development of new drugs that are not cross-resistant to platinum-based multi-drug therapies is essential.
A previous comparative Phase III study showed that topotecan had at least the same efficacy as paclitaxel (11) . In addition, a cross-over study of topotecan and paclitaxel revealed that topotecan had similar efficacy to paclitaxel, suggesting that topotecan shows no cross-resistance (11) . Clinical studies conducted in other countries in patients with ovarian carcinoma have shown efficacy using a regimen incorporating topotecan 1.5 mg/m 2 /day for five consecutive days (3 -6) . Today, topotecan is widely used in more than 80 countries, and treatment guidelines recommend it as a 
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Topotecan for relapsed ovarian carcinoma second-line treatment for ovarian carcinoma in patients with platinum-resistant, relapsed ovarian carcinoma (12, 13) . In the first Japanese early Phase II clinical trial, 1.2 mg/ m 2 was administered to patients who had been administered no more than two pretreatment regimens for relapsed ovarian carcinoma, but none of the patients met the criteria of CR and PR. However, 20% or greater reduction in tumor size was seen in 6 of 15 patients, and for that reason the second early Phase II clinical trial was carried out. In the second early Phase II clinical trial, which enrolled only patients who had been administered one previous chemotherapy regimen for relapsed ovarian carcinoma, PR was seen in 2 of 7 (28.6%) patients who were administered the 1.2 mg/m 2 dose. It was thus thought that the safety of the treatment using a topotecan dose of 1.2 mg/m 2 was acceptable. Myelosuppression, which is considered to be the major toxicity associated with topotecan, was tolerable.
On the basis of those results, we conducted the present Phase II study using the same regimen to investigate the efficacy, safety and pharmacokinetics of topotecan. In the present study, analysis of the antitumor effects of topotecan showed that the RR was 28.2% (95% CI, 18.1 -40.1%). The RR results of studies conducted in other countries have been 16.3% (95% CI, 9.4 -23.5%) in a Phase II study (4), 13.7% Table 5 . Pharmacokinetic parameters of the closed-ring form of topotecan and total topotecan on day 1 and day 5 when topotecan was administered at 1.2 mg/m 2 /day Pharmacokinetic parameter (6) . Since platinum-relapsed, -resistant and -sensitive patients were enrolled in those studies (4 -6) , as in our present study, these RR results can be considered comparable. Especially in patients with recurrence at more than 6 months after the first treatment, an RR of 37.8% was observed in our study. The RR for patients classified into this group was reported to be 26.7% (8 of 30 patients) (4) and 28.8% (15 of 52) (6) . In terms of the efficacy, these data support the use of topotecan 1.2 mg/m 2 /day in Japanese patients with relapsed ovarian carcinoma and suggest that topotecan may be effective.
Non-hematological adverse drug reactions to topotecan were generally transient and well tolerated. Diarrhea, which is one of the dose-limiting toxicities of irinotecan hydrochloride hydrate, a pharmacologically similar drug, was observed in 23 of the 72 patients. However, Grade 3 diarrhea occurred in only one patient (one of 371 cycles), and there were no Grade 4 events.
Regarding the incidences of adverse drug reactions, including Grade 3 or 4 neutropenia, leukopenia, thrombocytopenia and decreased Hb, there were no marked differences between this study and other studies. However, since topotecan may potentially cause such hematological toxicities, frequent monitoring of the peripheral blood should be performed, and if any abnormalities occur, appropriate management, including administration of G-CSF, transfusion and use of antibiotics, should be performed.
In contrast, Grade 4 thrombocytopenia occurred in only 4.2% of the Japanese patients in the present study administering topotecan 1.2 mg/m 2 , whereas it occurred in 18 -30.1% of patients in the studies using topotecan 1.5 mg/m 2 (4 -6). Therefore, the topotecan 1.2 mg/m 2 regimen may be considered more tolerable when treating patients with myelosuppression.
No clear dose -response relationship was found, but the reduced dose regimen (i.e. 1.0 mg/m 2 ) may be widely adopted for patients with a low therapeutic index.
The pharmacokinetic parameters of topotecan in this study were comparable with those in patients administered a dosage of 1.25 mg/m 2 in an earlier American Phase I study (8) . The results thus suggest that there are no remarkable differences in the plasma pharmacokinetics of topotecan between Japanese and non-Japanese patients.
In conclusion, the present study results suggest that topotecan 1.2 mg/m 2 /day may be an effective and tolerable therapeutic option in Japanese patients with relapsed ovarian carcinoma.
